Zika virus: New emergencies, potential for severe complications, & prevention of transfusion-Transmitted Zika fever in the context of co-circulation of arboviruses

Blood Transfusion

Volumn 15, Issue 3, 2017, Pages 272-273

  Musso, Didier ^a   Aubry, Maite ^a   Broult, Julien ^b   Stassinopoulos, Adonis ^c   Green, Jennifer ^c  

^a Institut Louis Malarde   (France)

^b Taone Hospital   (France)

^c CERUS CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN;

BLOOD TRANSFUSION; CHIKUNGUNYA; EMERGENCY; EPIDEMIC; GUILLAIN BARRE SYNDROME; HUMAN; LETTER; MICROCEPHALY; NONHUMAN; NUCLEIC ACID ANALYSIS; VIRUS INACTIVATION; VIRUS TRANSMISSION; ZIKA FEVER; ARBOVIRUS; ZIKA VIRUS;

ARBOVIRUSES; BLOOD TRANSFUSION; EMERGENCIES; HUMANS; ZIKA VIRUS; ZIKA VIRUS INFECTION;

EID: 85020099753     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2016.0003-16     Document Type: Letter

References (6)

1. Marano G, Pupella S, Vaglio S, et al. Zika virus and the neverending story of emerging pathogens and transfusion medicine. Blood Transfus 2016; 14: 95-100.
2. European Centre for Disease Prevention and Control. Rapid risk assessment. Zika virus disease epidemic: potential association with microcephaly and Guillain-Barré syndrome. Second update, 8 February 2016. Stockholm: ECDC; 2016.
3. Musso D, Nhan T, Robin E, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. Euro Surveill 2014; 19: pii: 20761.
4. Gallian P, Richard P, Maire F, et al. Chikungunya epidemic in the Caribbean: preventive measures by the French transfusion public service (Etablissement français du sang). Transfusion 2015; 55 (Suppl 3): 17A.
5. Aubry M, Richard V, Green J, et al. Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illumination. Transfusion 2016; 56: 33-40.
6. Food and Drug Administration. Recommendations for donor screening, deferral, and product management to reduce the risk of transfusion-Transmission of Zika virus. Guidance for industry. FDA; 2016. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM486360.pdf. Accessed on 01/03/2016.